Médicaments du groupe ATC L — Antinéoplasiques et immunomodulateurs
Aperçu des médicaments de la classe ATC L (Antinéoplasiques et immunomodulateurs) et leur disponibilité dans les pharmacies belges.
1855 médicaments
- Ibrance 100 mg — palbociclib
- Ibrance 125 mg — palbociclib
- Ibrance 125 mg — palbociclib
- Ibrance 125 mg — palbociclib
- Ibrance 75 mg — palbociclib
- Ibrance 75 mg — palbociclib
- Ibrance 75 mg — palbociclib
- Iclusig 15 mg — ponatinib
- Iclusig 15 mg — ponatinib
- Iclusig 30 mg — ponatinib
- Iclusig 45 mg — ponatinib
- Idacio 40 mg — adalimumab
- Idacio 40 mg — adalimumab
- Idacio 40 mg — adalimumab
- Idacio 40 mg — adalimumab
- Idacio 40 mg — adalimumab
- Idacio 40 mg — adalimumab
- Idacio 40 mg/0.8 ml
- Idarubicin Sandoz 1 mg/ml
- Idarubicin Sandoz 1 mg/ml
- Idarubicin Sandoz 1 mg/ml
- Idefirix 11 mg — imlifidase
- Ilaris 150 mg
- Ilaris 150 mg/ml — canakinumab
- Ilumetri 100 mg — tildrakizumab
- Ilumetri 100 mg — tildrakizumab
- Ilumetri 200 mg — tildrakizumab
- Imatinib Accord 100 mg — imatinib
- Imatinib Accord 100 mg — imatinib
- Imatinib Accord 100 mg — imatinib
- Imatinib Accord 400 mg — imatinib
- Imatinib Accord 400 mg — imatinib
- Imatinib Accord 400 mg — imatinib
- Imatinib Accord 400 mg — imatinib
- Imatinib EG 100 mg — imatinib
- Imatinib EG 100 mg — imatinib
- Imatinib EG 100 mg — imatinib
- Imatinib EG 400 mg — imatinib
- Imatinib EG 400 mg — imatinib
- Imatinib EG 400 mg — imatinib
- Imatinib Grindeks 100 mg — imatinib
- Imatinib Krka 100 mg — imatinib
- Imatinib Krka 400 mg — imatinib
- Imatinib Krka d.d. 100 mg
- Imatinib Krka d.d. 400 mg
- Imatinib Krka d.d. 400 mg
- Imatinib Mylan 100 mg
- Imatinib Mylan 400 mg
- Imatinib Mylan 400 mg
- Imatinib Sandoz 100 mg — imatinib
- Imatinib Sandoz 400 mg — imatinib
- Imatinib Teva 100 mg — imatinib
- Imatinib Teva 400 mg — imatinib
- Imbruvica 140 mg — ibrutinib
- Imbruvica 140 mg — ibrutinib
- Imbruvica 140 mg — ibrutinib
- Imbruvica 140 mg — ibrutinib
- Imbruvica 280 mg — ibrutinib
- Imbruvica 420 mg — ibrutinib
- Imbruvica 420 mg — ibrutinib